ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cell > PSMA > CHEK-ATP185

HEK293/Human PSMA Stable Cell Line

This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
  • Description
    HEK293/Human PSMA Stable Cell Line
  • Application

    Useful for cell-based PSMA binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    DMEM + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
  • Background
    Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

コメント (0)

価格(JPY) : 980,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:5 Details
  • Number of Drugs in Clinical Trials:72 Details
  • Latest Research Phase:Approved

データシート&ドキュメンテーション

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone